1
|
Zeng L, Cai H, Qiu A, Zhang D, Lin L, Lian X, Chen M. Risk factors for rehospitalization within 90 days in patients with total joint replacement: A meta-analysis. Medicine (Baltimore) 2023; 102:e35743. [PMID: 37960764 PMCID: PMC10637554 DOI: 10.1097/md.0000000000035743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Accepted: 09/29/2023] [Indexed: 11/15/2023] Open
Abstract
BACKGROUND The risk factors influencing the readmission within 90 days following total joint replacement (TJR) are complex and heterogeneous, and few systematic reviews to date have focused on this issue. METHODS Web of Science, Embase, PubMed, and Chinese National Knowledge Infrastructure databases were searched from the inception dates to December 2022. Relevant, published studies were identified using the following keywords: risk factors, rehospitalization, total hip replacement, total knee replacement, total shoulder replacement, and total joint replacement. All relevant data were collected from the studies that meet the inclusion criteria. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale (NOS). RESULTS Of 68,336 patients who underwent TJR, 1,269,415 (5.4%) were readmitted within 90 days. High American Society of Anesthesiologists (ASA) class (OR, 1.502; 95%CI:1.405-1.605; P < .001), heart failure (OR,1.494; 95%CI: 1.235-1.754; P < .001), diabetes (OR, 1.246; 95%CI:1.128-1.377; P < .001), liver disease (OR, 1.339; 95%CI:1.237-1.450; P < .001), drinking (OR, 1.114; 95%CI:1.041-1.192; P = .002), depression (OR, 1.294; 95%CI:1.223-1.396; P < .001), urinary tract infection (OR, 5.879; 95%CI: 5.119-6.753; P < .001), and deep vein thrombosis (OR, 10.007; 95%CI: 8.787-11.396; P < .001) showed statistically positive correlation with increased 90-day readmissions after TJR, but high blood pressure, smoking, and pneumonia had no significant association with readmission risk. CONCLUSION The findings of this review and meta-analysis will aid clinicians as they seek to understand the risk factors for 90-day readmission following TJR. Clinicians should consider the identified key risk factors associated with unplanned readmissions and develop strategies to risk-stratify patients and provide dedicated interventions to reduce the rates of readmission and enhance the recovery process.
Collapse
Affiliation(s)
- Liping Zeng
- Department of Orthopaedics, No. 910 Hospital of The Chinese People's Liberation Army Joint Logistic Support Force, Quanzhou, China
| | | | | | | | | | | | | |
Collapse
|
2
|
Tatipamula VB, Thonangi CV, Dakal TC, Vedula GS, Dhabhai B, Polimati H, Akula A, Nguyen HT. Potential anti-hepatocellular carcinoma properties and mechanisms of action of clerodane diterpenes isolated from Polyalthia longifolia seeds. Sci Rep 2022; 12:9267. [PMID: 35661799 PMCID: PMC9166726 DOI: 10.1038/s41598-022-13383-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Accepted: 05/24/2022] [Indexed: 11/23/2022] Open
Abstract
Diterpenes are secondary metabolites that have attracted much attention due to their potential biological activities including anti-cancer potential. The aim of the current study is to assess the anticancer potential of the six known clerodane diterpenes (1–6) isolated from Polyalthia longifolia seeds and their underlying molecular mechanisms. These compounds were evaluated for their cytotoxicity in vitro by using MTT assays. The “two-phase model” with NDEA and PB ad libitum was used for induction of HCC and sorafenib was used as the standard drug. Prophylactic studies were carried out for compounds 4/6 at both low (5 mg/kg b.w) and high (10 mg/kg b.w) doses. Based on the MTT assay results, the two best compounds, 4 and 6, were selected for in vivo studies. The results showed that treatment with compound 4/6 significantly restored the changes in biochemical parameters and liver morphology observed in (NDEA + PB)-induced HCC rats. Additionally, the docking studies showed that compound 4/6 interacted with several key proteins such as MDM2, TNF-α, FAK, thereby inhibiting these proteins and reversing the negative impacts of NDEA. In conclusion, our results suggested that compounds 4 and 6 are potential therapeutic agents for HCC, mostly due to their ability to control typical cancer pathways.
Collapse
Affiliation(s)
- Vinay Bharadwaj Tatipamula
- Center for Molecular Biology, College of Medicine and Pharmacy, Duy Tan University, Danang, 550000, Vietnam
| | - Chandi Vishala Thonangi
- Pharmacology Department, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, 530003, India.
| | - Tikam Chand Dakal
- Genome & Computational Biology Lab, Department of Biotechnology, Mohanlal Sukhadia University, Udaipur, Rajasthan, 313001, India
| | - Girija Sastry Vedula
- Pharmacology Department, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, 530003, India
| | - Bhanupriya Dhabhai
- Genome & Computational Biology Lab, Department of Biotechnology, Mohanlal Sukhadia University, Udaipur, Rajasthan, 313001, India
| | - Haritha Polimati
- Pharmacology Department, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, 530003, India
| | - Annapurna Akula
- Pharmacology Department, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, 530003, India
| | - Ha Thi Nguyen
- Center for Molecular Biology, College of Medicine and Pharmacy, Duy Tan University, Danang, 550000, Vietnam.
| |
Collapse
|
3
|
Mooli RGR, Mukhi D, Ramakrishnan SK. Oxidative Stress and Redox Signaling in the Pathophysiology of Liver Diseases. Compr Physiol 2022; 12:3167-3192. [PMID: 35578969 PMCID: PMC10074426 DOI: 10.1002/cphy.c200021] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The increased production of derivatives of molecular oxygen and nitrogen in the form of reactive oxygen species (ROS) and reactive nitrogen species (RNS) lead to molecular damage called oxidative stress. Under normal physiological conditions, the ROS generation is tightly regulated in different cells and cellular compartments. Any disturbance in the balance between the cellular generation of ROS and antioxidant balance leads to oxidative stress. In this article, we discuss the sources of ROS (endogenous and exogenous) and antioxidant mechanisms. We also focus on the pathophysiological significance of oxidative stress in various cell types of the liver. Oxidative stress is implicated in the development and progression of various liver diseases. We narrate the master regulators of ROS-mediated signaling and their contribution to liver diseases. Nonalcoholic fatty liver diseases (NAFLD) are influenced by a "multiple parallel-hit model" in which oxidative stress plays a central role. We highlight the recent findings on the role of oxidative stress in the spectrum of NAFLD, including fibrosis and liver cancer. Finally, we provide a brief overview of oxidative stress biomarkers and their therapeutic applications in various liver-related disorders. Overall, the article sheds light on the significance of oxidative stress in the pathophysiology of the liver. © 2022 American Physiological Society. Compr Physiol 12:3167-3192, 2022.
Collapse
Affiliation(s)
- Raja Gopal Reddy Mooli
- Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Dhanunjay Mukhi
- Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Sadeesh K Ramakrishnan
- Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| |
Collapse
|
4
|
Metabolite profiling of mice under long-term fructose drinking and vitamin D deficiency: increased risks for metabolic syndrome and nonalcoholic fatty liver disease. J Physiol Biochem 2020; 76:587-598. [DOI: 10.1007/s13105-020-00764-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Accepted: 08/12/2020] [Indexed: 02/07/2023]
|
5
|
Zhang Y, Jiang X, Li X, Găman MA, Kord-Varkaneh H, Rahmani J, Salehi-Sahlabadi A, Day AS, Xu Y. Serum Vitamin D Levels and Risk of Liver Cancer: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies. Nutr Cancer 2020; 73:1-9. [PMID: 32705896 DOI: 10.1080/01635581.2020.1797127] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Data regarding the relationship between serum vitamin D levels and the risk of liver cancer are conflicting. Therefore, we performed a systematic review and dose-response meta-analysis of all available data of cohort studies on the association of 25-OH-vitamin-D levels with the risk of hepatocellular carcinoma. We conducted a systematic search in PubMed-MEDLINE, Scopus, Cochrane and Web of Science databases for prospective observational studies conducted on the general population from inception to May 2019. Six studies provided data from 6357 participants. According to the pooled HR, the subjects with the highest serum concentrations of vitamin D had a 47% lower risk of liver cancer vs. the subjects with the lowest serum concentrations of vitamin D (pooled HR: 0.53, 95% CI: 0.41-0.68; P < 0.001). There was no significant heterogeneity among the studies (P = 0.431, I2 = 0.0). The pooled HR from the random-effects dose-response model indicated an indirect significant linear association between vitamin D and the risk of liver cancer (coef = -0.017, P < 0.001). However, there was no significant nonlinear dose-response association between serum vitamin D and the risk of liver cancer (coef = -0.0001, P = 0.342). The evidence from this meta-analysis suggests that there may be an inverse relationship between serum vitamin D levels and the risk of liver cancer.
Collapse
Affiliation(s)
- Yonggui Zhang
- Department of Gastroenterology, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Xuefeng Jiang
- Department of Gastroenterology, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Xiangjun Li
- Department of Experimental Pharmacology and Toxicology, School of Pharmaceutical Science, Jilin University, Changchun, China
| | - Mihnea-Alexandru Găman
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| | - Hamed Kord-Varkaneh
- Department of Clinical Nutrition and Dietetics, Student Research Committee, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Jamal Rahmani
- Department of Clinical Nutrition and Dietetics, Student Research Committee, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Ammar Salehi-Sahlabadi
- Department of Clinical Nutrition and Dietetics, Student Research Committee, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Andrew S Day
- Department of Paediatrics, University of Otago, Christchurch, New Zealand
| | - Yan Xu
- Department of Gastroenterology, China-Japan Union Hospital of Jilin University, Changchun, China
| |
Collapse
|
6
|
Daher A, Matsuoka CK, Loghin ME, Penas-Prado M, Tummala S. Neuromuscular Weakness Syndromes from Immune Checkpoint Inhibitors: A Case Series and Literature Review. ACTA ACUST UNITED AC 2019. [DOI: 10.4103/jipo.jipo_3_19] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Abstract
Immune checkpoint inhibitors (CPIs) (anti-cytotoxic T-lymphocyte antigen-4, anti-programmed death 1, and anti-programmed death-ligand 1) have transformed the landscape of cancer therapy. However, their increasing use has unleashed immune-related adverse events in various organs, among which neurologic ones, while rare, are increasingly being recognized and remain incompletely characterized. Herein, we report five patients with nonmelanoma cancers who developed weakness after receiving CPIs. The etiology was attributed to radiculoneuritis (one patient), myositis (one patient), Miller Fisher/myasthenia gravis (MG) (one patient), neuropathy/myositis/MG (one patient), and myositis/MG (one patient). Weakness developed after a median of two doses (range: 1–3) and 4 weeks (range: 3–10) from initiation of therapy. Two patients had severe manifestations without improvement while the other three experienced partial improvement despite discontinuation of the CPI (s) and initiation of immunosuppressive therapy. A review of literature identified 62 similar cases. This report highlights the challenges in the diagnosis and management of neurologic adverse events related to the use of CPIs. It also addresses the crucial need for early recognition, proper workup, and better biomarkers to help improve the outcomes of these adverse events.
Collapse
Affiliation(s)
- Ahmad Daher
- Department of Neuro-Oncology, Hartford Health Care Medical Group, Hartford Hospital, Hartford, CT
| | - Carlos Kamiya Matsuoka
- Department of Neuro-Oncology, Hartford Health Care Medical Group, Hartford Hospital, Hartford, CT
- Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Monica Elena Loghin
- Department of Neuro-Oncology, Hartford Health Care Medical Group, Hartford Hospital, Hartford, CT
- Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Marta Penas-Prado
- Department of Neuro-Oncology, Hartford Health Care Medical Group, Hartford Hospital, Hartford, CT
- Department of Neuro-Oncology Branch, National Cancer Institute, Bethesda, MD, USA
| | - Sudhakar Tummala
- Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
| |
Collapse
|
7
|
Khan S, Ali A, Khan S, Bakillah A, Damanhouri G, Khan A, Makki A, AlAnsari I, Banu N. Correction to: Current therapies in alleviating liver disorders and cancers with a special focus on the potential of vitamin D. Nutr Metab (Lond) 2018; 15:21. [PMID: 29569628 PMCID: PMC5857078 DOI: 10.1186/s12986-018-0257-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Accepted: 03/13/2018] [Indexed: 11/16/2022] Open
Affiliation(s)
- Shahida Khan
- 1Applied Nutrition and Natural Products Group, King Fahd Medical Research Center, King Abdulaziz University, P.O.Box 80216, Jeddah, 21589 Kingdom of Saudi Arabia
| | - Ashraf Ali
- 1Applied Nutrition and Natural Products Group, King Fahd Medical Research Center, King Abdulaziz University, P.O.Box 80216, Jeddah, 21589 Kingdom of Saudi Arabia
| | - Sarah Khan
- 2National Brain Research Center, Manesar, Gurgaon, 122051 India
| | - Ahmed Bakillah
- 3Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203 USA
| | - Ghazi Damanhouri
- 1Applied Nutrition and Natural Products Group, King Fahd Medical Research Center, King Abdulaziz University, P.O.Box 80216, Jeddah, 21589 Kingdom of Saudi Arabia
| | - Aziz Khan
- 1Applied Nutrition and Natural Products Group, King Fahd Medical Research Center, King Abdulaziz University, P.O.Box 80216, Jeddah, 21589 Kingdom of Saudi Arabia
| | - Ahmad Makki
- 1Applied Nutrition and Natural Products Group, King Fahd Medical Research Center, King Abdulaziz University, P.O.Box 80216, Jeddah, 21589 Kingdom of Saudi Arabia
| | - Ibtehal AlAnsari
- 1Applied Nutrition and Natural Products Group, King Fahd Medical Research Center, King Abdulaziz University, P.O.Box 80216, Jeddah, 21589 Kingdom of Saudi Arabia
| | - Naheed Banu
- 4Department of Biochemistry, College of Medical Rehabilitation, Buraydah, Qassim University, P.O. Box 51452, Qassim, Kingdom of Saudi Arabia
| |
Collapse
|